4-Aminopyridine clinical trials
Also written Ampyra, Dalfampridine, Fampyra and BIIB041.
How each study uses 4-Aminopyridine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the 4-Aminopyridine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 22 Jan 2010 · AMPYRA · NDA 022250 (FDA, Drugs@FDA)
- European Union
- 20 Jul 2011 · Fampyra · EMEA/H/C/002097 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
59 studies that test it; most in 2014 (8); 1 more planned to start later
| Year | Studies |
|---|---|
| 2002 | 3 |
| 2003 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 6 |
| 2013 | 4 |
| 2014 | 8 |
| 2015 | 2 |
| 2016 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 3 |
| 2024 | 1 |
| 2025 | 5 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 45
Acorda Therapeutics (10) · Biogen (6) · John Elfar (4) · Prof. Dominique de Quervain, MD (3) · University of Southern Denmark (3) · Shirley Ryan AbilityLab (2) · Coordinación de Investigación en Salud, Mexico (2) · Milton S. Hershey Medical Center (2)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Potassium channel blockers source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 6, 3 in phase 3
Studies that test 4-Aminopyridine, phase 3 first.
- May 2027Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple SclerosisPhase 3 · MGH Institute of Health Professions
- May 2027A Randomized, Parallel-arm, Double Blind, Placebo-controlled Study to Assess the Efficacy of Fampridine for Patients With Spinocerebellar Ataxia SCA27B Caused by a GAA Expansion in the FGF14 GenePhase 3 · Assistance Publique - Hôpitaux de Paris
- Jul 20274-aminopyridine Treatment for Nerve InjuryPhase 2/3 · John Elfar
- Mar 2027Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate DepressionPhase 2 · University of Basel
- Aug 2027The Role of Potassium Channels in Working Memory Impairments of Chronic Cocaine UsersNot applicable · Boris Quednow
- Sep 20274-aminopyridine for Skin Wound HealingPhase 2 · John Elfar
Studies
Open first, then newest update. How each study uses 4-Aminopyridine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 61
- Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple SclerosisRecruitingPhase 3MGH Institute of Health ProfessionsNCT06136728Written as Dalfampridine 10 MG [Ampyra]How we know
- Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate DepressionRecruitingPhase 2University of BaselNCT06751784Written as Fampridine SRHow we know
- Single Dose 4-Aminopyridine for Diagnosing Recurrent Laryngeal Nerve Paralysis Continuity After TraumaNot yet recruitingPhase 1Milton S. Hershey Medical CenterNCT07832331Written as 4-AminopyridineHow we know
- The Role of Potassium Channels in Working Memory Impairments of Chronic Cocaine UsersRecruitingNot applicableBoris QuednowNCT07532460Written as 4-aminopyridine (4-AP)How we know
- Double Dose 4-AP on Functional Recovery After Spinal Cord InjuryRecruitingPhase 1/2Shirley Ryan AbilityLabNCT06853015Written as DalfampridineHow we know
- Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal TumorRecruitingPhase 1University of California, San DiegoNCT07171203Written as FampridineHow we know
- 4-Aminopyridine to Treat Skin BurnsRecruitingPhase 2John ElfarNCT06596434Written as Drug: 4-AminopyridineHow we know
- 4AP for Carpal Tunnel Syndrome (CTS)Not yet recruitingPhase 2John ElfarNCT06294821Written as 4-AminopyridineHow we know
- 4-aminopyridine Treatment for Nerve InjuryRecruitingPhase 2/3John ElfarNCT03701581Written as 4-AminopyridineHow we know
- A Randomized, Parallel-arm, Double Blind, Placebo-controlled Study to Assess the Efficacy of Fampridine for Patients With Spinocerebellar Ataxia SCA27B Caused by a GAA Expansion in the FGF14 GeneRecruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT07185347Written as Fampridine 10 mg prolonged-release tablet (per os)How we know
- 4-aminopyridine for Skin Wound HealingRecruitingPhase 2John ElfarNCT06333171Written as 4-AminopyridineHow we know
- 4-AP Peripheral Nerve Crossover TrialRecruitingPhase 2University of ArizonaNCT06003166Written as 4-AminopyridineHow we know
- Use of Dalfampridine in Primary Lateral SclerosisCompletedPhase 1Hospital for Special Surgery, New YorkNCT02868567Written as dalfampridineHow we know
- Effects of 4-AP on Functional SCI RecoveryCompletedEarly Phase 1Shirley Ryan AbilityLabNCT05447676Written as DalfampridineHow we know
- Influence of Fampridine on Working Memory in Healthy SubjectsWithdrawnPhase 2Prof. Dominique de Quervain, MDNCT04516603Written as Fampridine SRHow we know
- Short and Long Term Treatment With 4-AP in Ambulatory SMA PatientsCompletedPhase 2/3Columbia UniversityNCT01645787Written as 4-aminopyridineHow we know
- Influence of Fampridine on Working Memory in Individuals With Post COVID-19 Condition With Subjective Cognitive ImpairmentTerminatedNot applicableProf. Dominique de Quervain, MDNCT05274477Written as Fampridine SRHow we know
- 4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular MigraineWithdrawnPhase 2Massachusetts Eye and Ear InfirmaryNCT03578354Written as 4-aminopyridineHow we know
- Dalfampridine in Egyptian Patients With Multiple SclerosisStatus unknownNot applicableAin Shams UniversityNCT05730738Written as Dalfampridine ER, 10 Mg Oral Tablet, Extended ReleaseHow we know
- Influence of Fampridine on Working Memory in Healthy Young SubjectsCompletedPhase 2Prof. Dominique de Quervain, MDNCT04652557Written as Fampridine SRHow we know
Codes
What other systems call 4-Aminopyridine · ClinicalTrials.gg INT008495
- MeSH (NLM) D0157614-AminopyridineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) BH3B64OKL9DALFAMPRIDINEConfirmed FDA, NLM
- RxNorm 897018One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D015761 | 4-Aminopyridine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | BH3B64OKL9 | DALFAMPRIDINE | Confirmed FDA, NLM |
| RxNorm | 897018 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.